Galderma (a/k/a Nestlé Skin Health) could acquire RVNC if they returned their Dysport rights to Ipsen, which they would probably be happy to do if they could obtain a better product (i.e. RT002). Moreover, acquiring RVNC would give Galderma entry to the therapeutic side of the botulinum-toxin market, which they don’t currently have.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.